Pharmacokinetics of mercaptopurine: Plasma drug and red cell metabolite concentrations after an oral dose

Therapeutic Drug Monitoring

Volumn 19, Issue 4, 1997, Pages 382-385

  Welch, Jennifer ^a   Lennard, Lynne ^a,c   Morton, Gillian C A ^a   Lilleyman, John S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

6 Mercaptopurine; 6 Thioguanine nucleotides; Methylmercaptopurines; Red Cells; Stability

Indexed keywords

DRUG METABOLITE; MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; STEROID; TIOGUANINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; TABLET;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; THIONUCLEOTIDES; TIME FACTORS;

EID: 0031423967     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199708000-00003     Document Type: Article

References (14)

1. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343: 1188-1190.
2. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukaemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-292.
3. Hayder S, Lafolie P, Bjork O, Peterson C. 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukaemia: Relation to relapse risk and myelotoxicity. Ther Drug Monit 1989; 11:617-622.
4. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 1983;308:1005-1009.
5. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-229.
6. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995;72:1004-1006.
7. Lennard L, Singleton H. High performance liquid Chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatog 1992;583:83-90.
8. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Childh 1993;69:577-579.
9. Lennard L, Lilleyman JS. Are children with lymphoblastic leukaemia given enough 6-mercaptopurine? Lancet 1987;ii:785-787.
10. Bokkerink JPM, Stet EH, de Abreu RRA, et al. 6-mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 1994;45:1455-1463.
11. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-662.
12. Lennard L, Lilleyman JS. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia. J Clin Oncol 1989;7:1816-1823.
13. Chessells JM, Bailey CC, Richards SM. Intensification of treatment improves survival for all children with lymphoblastic leukaemia: results of MRC UKALL X. Lancet 1995;345:143-148.
14. Lennard L, Hale JP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 1993;36:277-284.